OSTEOPOROSIS AND OSTEOARTHRITIS The prefix “osteo” (which means “bone”) is the only thing that osteoporosis and osteoarthritis have in common. Despite the fact that osteoporosis, arthritis and osteoarthritis (a form […]

  BÜBL™ WINS BRONZE LION This year, Osteoporosis Canada launched a transformative campaign intended to disrupt the osteoporosis landscape, while shining a light on a disease that affects 2 million […]

FRACTURE RISK ASSESSMENT Determining your risk of breaking a bone Rather than relying solely on the results of a bone mineral density (BMD) test to make treatment decisions for osteoporosis, […]

Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

DIAGNOSIS The importance of a comprehensive fracture risk assessment Insist on Assessment Osteoporosis often goes undiagnosed until a bone fractures, and is therefore commonly referred to as “the silent thief”. […]

Do you use the Internet to search for information, particularly medical and health related information? Are you ever tempted to self-diagnose or even self-medicate because of something you have read […]

Tools Algorithm 1 Integrated approach to the management of bone health and fracture prevention in postmenopausal females and males 50 years and older. DOWNLOAD Algorithm 2 Approach to pharmacotherapy to […]

There has been recent media coverage concerning a rare atypical femoral fracture that may be a side effect of denosumab (Prolia), an osteoporosis medication manufactured by Amgen. Osteoporosis Canada’s Scientific […]

Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada Calcium is essential for the achievement and maintenance of normal bone health. The current daily requirements for […]